NVCT (Nuvectis Pharma) YoY EPS Growth : 12.20% (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Nuvectis Pharma YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Nuvectis Pharma's YoY EPS Growth for the quarter that ended in Dec. 2024 was 12.20%.

Nuvectis Pharma's Earnings per Share (Diluted) for the three months ended in Dec. 2024 was $-0.36.

Nuvectis Pharma YoY EPS Growth Historical Data

The historical data trend for Nuvectis Pharma's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvectis Pharma YoY EPS Growth Chart

Nuvectis Pharma Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

YoY EPS Growth

-38.41

5.30

22.38

Nuvectis Pharma Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
YoY EPS Growth	Get a 7-Day Free Trial												14.58	7.41	31.58	35.14	12.20

Nuvectis Pharma YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Nuvectis Pharma's YoY EPS Growth for the fiscal year that ended in Dec. 2024 is calculated as:

	YoY EPS Growth (A: Dec. 2024 )
=	(Earnings per Share (Diluted) (A: Dec. 2024 )	-	Earnings per Share (Diluted) (A: Dec. 2023 ))	/	\| Earnings per Share (Diluted) (A: Dec. 2023 ) \|
=	(-1.11	-	-1.43)	/	\| -1.43 \|
=	22.38 %

Nuvectis Pharma's YoY EPS Growth for the quarter that ended in Dec. 2024 is calculated as:

	YoY EPS Growth (Q: Dec. 2024 )
=	(Earnings per Share (Diluted) (Q: Dec. 2024 )	-	Earnings per Share (Diluted) (Q: Dec. 2023 ))	/	\| Earnings per Share (Diluted) (Q: Dec. 2023 )) \|
=	(-0.36	-	-0.41)	/	\| -0.41 \|
=	12.20 %

Nuvectis Pharma YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Nuvectis Pharma's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuvectis Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvectis Pharma Inc (NAS:NVCT) » Definitions » YoY EPS Growth

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, NJ, USA, 07024

Website

https://www.nuvectis.com

Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.

Executives

Marlio Charles Mosseri	10 percent owner	27 RIPPLEVALE GROVE, LONDON X0 N1 1HS
Ron Bentsur	director, officer: Chairman & CEO	750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Enrique Poradosu	officer: Chief Science and Business Off	C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, FORT LEE NJ 07024
Michael J. Carson	officer: Vice President, Finance	C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024
Shay Shemesh	officer: Chief Development Officer	C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024
Kenneth Hoberman	director	750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Oliviero James F Iii	director	C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Uri Ben-or	officer: Int. Principal Financial Off.	C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Matthew L. Kaplan	director	C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024